February Corporate Update Forward-Looking Statements These slides contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward-looking statements include those relating to, among other things, Chimerix's ability to develop its drug candidates including ONC201, DSTAT and BCV; the sufficiency of the data from the current clinical trial ...

Chimerix, Inc. (NASDAQ:CMRX) Q4 2020 Earnings Conference Call February 25, 2021 8:30 AM ET Company Participants Michelle LaSpaluto - VP, Strategic Planning & IR Mike Sherman - President & CEO Allen Melemed - CMO Mike Andriole - CFO/CBO Randall Lanier - CSO Josh Allen - Interim CTO Conference Call Participants Ed White - H.C. Wainwright Soumit Roy - Jones Trading Joseph Thome - Cowen and Company Operator Good morning, ladies and gentlemen, and welcome to the Chimerix Fourth Quarter and Year-End 2020 Earnings ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35867 Chimerix, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware (State or Other Jurisdiction of Incorporation or ...

November Corporate Update Forward-Looking Statements These slides contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward-looking statements include those relating to, among other things, Chimerix's ability to develop DSTAT and BCV, including the initiation, progress and results of the Phase 3 clinical trial of DSTAT in AML and t ...

Financial Data and Key Metrics Changes - The company reported a net loss of $11.4 million or $0.18 per basic and diluted share for Q3 2020, a significant decrease from a net loss of $73.7 million or $1.26 per share in Q3 2019 [24] - Revenues for Q3 2020 were $1.6 million, down from $2 million in the same period of 2019 [24] - Research and development expenses increased to $10 million in Q3 2020 from $7.5 million in Q3 2019, primarily due to clinical trial expenses for DSTAT [24] - General and administrative expenses decreased to $3.2 million in Q3 2020 from $4 million in Q3 2019 [24] - The company ended Q3 2020 with approximately $88 million in capital and no debt, expecting to finish the year with about $75 million in cash [23] Business Line Data and Key Metrics Changes - The company has successfully filed two separate NDAs for brincidofovir, focusing on its use as a smallpox countermeasure [5][6] - The decision to narrow the focus on brincidofovir led to the out-licensing of all other indications to SymBio [6] - The Phase III trial of DSTAT in acute myeloid leukemia (AML) is set to initiate early next year, with an early efficacy analysis planned for 80 patients [13][20] Market Data and Key Metrics Changes - The company is enhancing its relationship with BARDA, which remains engaged despite its COVID-19 activities, indicating a priority for obtaining a second smallpox antiviral [10][11] - The company anticipates a potential RFP from BARDA in Q1 2021, coinciding with the expected approval timeline [11] Company Strategy and Development Direction - The company is focused on fulfilling a critical public health need with the brincidofovir smallpox program while also aiming to provide substantial value to shareholders [25][26] - The strategy includes a modest investment in DSTAT for COVID-19, with expectations for significant upside potential [26] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism regarding the prospects of the brincidofovir submission and the potential for procurement contracts [11] - The company remains disciplined in resource allocation for trials, ensuring strong data-driven decisions [17] - Management highlighted the importance of MRD as an early indicator of efficacy in AML, which could accelerate the development of novel therapeutics [19] Other Important Information - The company plans to report interim data from the COVID study in Q1 2021 and looks forward to updates on AML clinical progress later in the year [22] Q&A Session Summary - The Q&A session concluded without any recorded questions or answers, indicating a focus on the presentation rather than interactive discussion [28]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35867 CHIMERIX, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 33-0903395 (State or Other Jurisdictio ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35867 CHIMERIX, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 33-0903395 (State or Other Jurisdiction of ...

Chimerix, Inc. (NASDAQ:CMRX) Q2 2020 Earnings Conference Call August 10, 2020 8:30 AM ET Company Participants Michelle LaSpaluto - Vice President, Strategic Planning & Investor Relations Mike Sherman - President & Chief Executive Officer Randall Lanier - Chief Science Officer Mike Andriole - Chief Financial & Business Officer Allen Melemed - Chief Medical Officer Conference Call Participants Phil Nadeau - Cowen and Company Soumit Roy - JonesTrading Operator Good morning, ladies and gentlemen and welcome to ...

July Corporate Update Forward-Looking Statements These slides contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward-looking statements include those relating to, among other things, Chimerix's ability to develop DSTAT and BCV, including the initiation of a Phase 2/3 clinical study for DSTAT in COVID-19 and a Phase 3 clinical tr ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35867 CHIMERIX, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 33-0903395 (State or Other Jurisdiction of ...